Expresión en cultivo celular de la proteína VP6 de rotavirus mediante el uso de vectores virales basados en HSV-1
Herpes simplex virus (HSV)-based vectors have been used as platforms for the generation of genetic vaccines against different viruses. Some of the advantages of defective HSV-1 vectors include: (a) HSV-1 can infect most cell types, including antigen-presenting cells; (b) HSV-1 vectors have a large transgene capacity (up to 150-kbp); (c) HSV-1 vectors can be designed to cause no toxicity; (d) different studies showed that mice vaccinated with such vectors encoding antigens from different pathogens were partially protected 1, 3 , indicating that HSV-1 based vectors are attractive tools for the development of safe genetic vaccines.
There are two main platforms of HSV-1-derived vectors: defective recombinant viruses (deleted in ICP4, ICP27 and ICP22 genes) and amplicons. Defective HSV-1 viruses can only be propagated using a complementing cell line. Production of amplicons depends on helper functions, provided in trans. In both systems, different genetic elements were intentionally introduced to conduct the heterologous gene expression and to allow the titration of the vector stocks in different cell lines 2, 4 . In our group, HSV-1 vectors were developed for the expression of several rotavirus genes. Genes from other pathogens were also expressed, thus generating a set of tools to be tested as new vaccine candidates against different diseases.
In this section, we show two different HSV-1 vectors that express the VP6 protein from different rotavirus strains. Figure 1 shows a defective recombinant virus expressing simultaneously Enhanced Green Fluorescent Protein (EGFP) and VP6 from murine rotavirus strain EC, in Figure 2 and movie S1, an amplicon vector overexpressing VP6 from a Wa strain of human rotavirus is shown. In both cases, the VP6 proteins were recognized by a monoclonal antibody and were found extensively expressed forming filaments along the cells, showing a typical intra-cellular pattern, in the absence of other rotavirus protein. These results show that the recombinant proteins maintain the specific capacity of self-assembly of the native protein and, therefore, are potential vaccine candidates to be explored. Recently, results obtained by our group and in collaboration with others, have demonstrated the feasibility of these systems to induce protective immune responses against different viral infections 1,3 .
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